AMYLOIDOSES: A MONOCENTRIQUE EXPERIENCE
Latifa Khelifa, Dghaies Salma, Mankai Roua, Tounsi Haifa, Skouri Wafa, Amri Raja
Internal Medecine Department MTM Nabeul, Tunisia

AUTOLOGOUS BMT AT FIRST LINE OF TREATMENT IN AL AMYLOIDOSIS WITHOUT CHEMOTHERAPY PREPARATION
Mehrdad Payandeh
Kermanshah University of Medical Sciences, Iran

CLINICAL CHARACTERISTICS AND OUTCOMES OF AL AMYLOIDOSIS PATIENTS IN SASKATCHEWAN: A POPULATION‐BASED COHORT STUDY
Samaneh Bayati1, Waleed Sabry1,2, Mahsa Moosavi3, Ali Khan1, Abdulhakim Eswedi1,4, and Ibraheem Othman1,4
1College of Medicine, University of Saskatchewan, Saskatoon; 2Division of Hematology, Department of Medical Oncology and Hematology, Saskatoon Cancer Centre, Saskatoon; 3Department of Mathematics and Statistics, University of Regina; 4Division of Hematology, Department of Medical Oncology and Hematology, Allan Blair Cancer Centre, Regina, Canada

REAL-LIFE EXPERIENCE ON LIGHT CHAIN CARDIAC AMYLOIDOSIS: DELAY IN DIAGNOSIS IS STILL A MAJOR ISSUE
Marie-Christiane Vekemans1, Morgane Thiry1, Will Smits2, Ornella Rizzo2, Nathalie Meuleman2
1UCL Saint Lc, Brussels, Belgium; 2HUB, ULB, Brussels, Belgium

REAL-WORLD 20 YEAR PFS AND OS DATA FROM TURKEY ON THE IMPACT OF THE INTRODUCTION OF DARATUMUMAB INTO THE TREATMENT OF AL AMYLOIDOSIS
Guldane Cengiz Seval1, Hulya Yilmaz1, Ece Vural2, Orhan Kemal Yucel3, Selami Kocak Toprak1, Meltem Kurt Yuksel1, Pervin Topcuoglu1, Meral Beksac2
1Ankara University School of Medicine Department of Hematology, 2Ankara Liv Hospital Department of Hematology, 3Akdeniz University School of Medicine Department of Hematology, Turkey             

10 YEARS ACTIVITY FOR AUTOLOGOUS BMT IN MYELOMA PATIENTS
Mehrdad Payandeh
Kermanshah University of Medical Sciences, Iran

A SUCCESSFUL CASE OF PRIMARY PLASMA CELL LEUKEMIA TREATED WITH DARATUMUMAB-BASED THERAPY FOLLOWED BY AUTOLOGOUS BONE MARROW TRANSPLANTATION
Viola Cavolli
Qendra Spitalore Universitare, Kosovo

COMPARISON OF SINGLE, TANDEM, AND SECOND AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN PATIENT WITH MULTIPLE MYELOMA (MM) AT SASKATCHEWAN CANCER AGENCY (SCA): A RETROSPECTIVE POPULATION-BASED STUDY
Seyedeh Zahra (Mona) Moossavi1, Waleed Sabry1,2, Mahsa Moosavi3, Ibraheem Othman1,4
1College of Medicine, University of Saskatchewan, Saskatoon, SK; 2Division of Hematology, Department of Medical Oncology and Hematology, Saskatoon Cancer Center, Saskatoon, SK; 3Department of Math and Statistics, University of Regina, Regina, SK; 4Division of Hematology, Department of Medical Oncology and Hematology, Allan Blair Cancer Center, Regina, SK, Canada

CRYOTHERAPY SIGNIFICANTLY REDUCES ORAL MUCOSITIS INCIDENCE IN MYELOMA PATIENTS UNDERGOING MELPHALAN-BASED AUTOLOGOUS STEM CELL TRANSPLANTATION: A COMPARATIVE STUDY
Joe Glover, Elisa Roldan-Galvan, Jose Cilleruelo, Sally Keat, Rhiannon Sweeney, Catherine Ellin
Sheffield Teaching Hospital NHS, UK

DARATUMUMAB-LENALIDOMIDE-DEXAMETHASONE IN PATIENS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA NOT CANDIDATES FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: EXPERIENCE AT OUR CENTER
María del Mar Fernández Sánchez, Laura García Tejero, María Esther Clavero Sánchez, Elena Masana Flores
Hospital Universitario Virgen de las Nieves, Granada, Spain

DIALYSIS AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: EXPERIENCE IN OUR CENTER
Carmen Gil Barroso, Rocío Zapata Bautista, Antonio Palma Vallellano, Cristina Vaz Silva, Pilar Pérez García
Hospital Juan Ramón Jiménez, Huelva, Spain

EVOLVING DEMOGRAPHICS AND OUTCOMES IN BONE MARROW TRANSPLANTATION FOR MULTIPLE MYELOMA: A RETROSPECTIVE ANALYSIS
Yehor Skibytskyi, Alevtina Burtna, Ksenia Bolgarina, Nataliia Shudrak, Viktoriia Harashchenko, Marina Bushuieva, Irina Kryachok, Nazarii Shokun
National Cancer Institute of Ukraine, Kyiv, Ukraine     

EXTRAMEDULLARY LOCALIZATION IN YOUNG PATIENTS WITH MULTIPLE MYELOMA ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION: A MULTICENTER TUNISIAN STUDY FROM THE NATIONAL TUNISIAN MULTIPLE MYELOMA STUDY GROUP
Faten Kallel1, Raoudha Mansouri2, Hela Ghedira3, Nesrine Ben Said4, Dorra Belloumi5, Sarra Boukhriss6, Latifa Khalifa1, Manel Bechir2, Wiem Boufrikha6, Sami Ziba3, Moez Medhaffar1, Tarek Ben Othmen2
1Hematology Department of Hedi Chaker Hospital; Hematology, Tunis; 2Department of Aziza Othmena Hospital; 3Hematology Department of Military Hospital, Tunis; 4Hematology Department of Farhat Hached Hospital; 5National Bone Marrow Transpalnt Center, Tunis; 6Hematology Department of Monastir Hospital, Monastir, Tunisia

FRESH AND CRYOPRESERVED STEM CELL TRANSPLANTATION IN MYELOMA PATIENTS: DOES IT MAKE A DIFFERENCE ON TRANSPLANT OUTCOMES?
Mehmet Ali Erkurt1, Seda Yilmaz2, Sinem Namdaroglu3, Sinan Demircioglu4, Ahmet Sarici1, Salih Cirik2, Mustafa Koroglu5, Mustafa Merter4, Semih Basci3, Ilhami Berber1, Abdulkadir Basturk2, Mehmet Sinan Dal6, Turgay Ulas6, Serdal Korkmaz7, Fevzi Altuntas6
1Inonu University, Faculty of Medicine, Department of Hematology and Bone Marrow Transplantation Unit; 2University of Health Sciences, Konya Medical Faculty, Department of Hematology and Bone Marrow Transplantation Unit; 3Dokuz Eylul University, Faculty of Medicine, Department of Hematology and Bone Marrow Transplantation Unit; 4Necmettin Erbakan University, Faculty of Medicine, Department of Hematology; 5Istinye University, School of Medicine, Internal Medicine Department, Hematology & Bone Marrow Transplantation Unit; 6Ankara Oncology Training and Research Hospital; 7Acibadem Mehmet Ali Aydinlar University Atakent Hospital, Department of Hematology and Bone Marrow Transplantation Unit, Turkey

INFECTIONS AND IMMUNE RECONSTITUTION IN THE PHASE 3 CARTITUDE-4 TRIAL OF CILTACABTAGENE AUTOLEUCEL VS STANDARD CARE IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA (MM) AND 1–3 PRIOR LINES
Joaquín Martínez-López1, Niels WCJ van de Donk2, Binod Dhakal3, Magdalena Dutka4, Leyla Shune5, Cyrille Touzeau6, Xavier Leleu7, Yaël C Cohen8, Winfried Alsdorf9, Roberto Mina10, Katherine Li11, Man Zhao12, Quanlin Li13, Arnab Ghosh14, Martin Vogel15, Nikoletta Lendvai14, Ana Slaughter16, Carolina Lonardi17, Vicki Plaks11, Mythili Koneru18, Nitin Patel18, Erika Florendo18, Albert Oriol19, Rakesh Popat20, P. Joy Ho21
1Hospital 12 de Octubre, Universidad Complutense, Centro Nacional de Investigaciones Oncológicas, CIBERONC, Madrid, Spain; 2Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; 3Medical College of Wisconsin, Milwaukee, WI, USA; 4Medical University of Gdańsk, Gdańsk, Poland; 5The University of Kansas Medical Center, Kansas City, KS, USA; 6Centre Hospitalier Universitaire de Nantes, Nantes, France; 7CHU Poitiers, Poitiers, France; 8Tel Aviv Sourasky (Ichilov) Medical Center, Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; 9University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 10AOU Città della Salute e della Scienza di Torino, Turin, Italy; 11Janssen Research & Development, Spring House, PA, USA; 12IQVIA, Shanghai, China; 13Janssen Research & Development, Apex, NC, USA; 14Janssen Research & Development, Raritan, NJ, USA; 15Janssen Research & Development, Neuss, Germany; 16Cilag GmbH International, Zug, Switzerland; 17Janssen, Buenos Aires, Argentina; 18Legend Biotech USA Inc., Somerset, NJ, USA; 19Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain; 20University College London Hospitals, NHS Foundation Trust, London, UK; 21Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia

REAL-LIFE ANALYSIS OF HEAVY-LIGHT CHAIN ASSAY IN MULTIPLE MYELOMA PATIENTS UNDERGOING TRANSPLANTATION
Antoni Garcia Guiñon1, Silvia Pico Fornies2, Xavier Gomez Arbones3, Yasmina Seres Fontanet1, Lucia Fraile Garcia2, Maria Font Font2, Armando Luaña Galan1, Ainara Ferrero Campos1, Eugenia Rivero Arango1, Izarbe Delgado Español1, Tomas Garcia Cerecedo1
1Arnau de Vilanova University Hospital, Hematology, Lleida; 2Arnau de Vilanova University Hospital, Laboratory, Lleida; 3Universitat de Lleida, Medicina, Lleida, Spain

RELAPSED MULTIPLE MYELOMA-DRIVEN HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS POST-AUTOLOGOUS STEM CELL TRANSPLANTATION: A CASE LINKING CYTOKINE OVERLOAD TO IMMUNE-CANCER CROSSTALK
Yanxi Huang1, Xi Huang1, Zhengjun Guo1, Yun Luo1, Chun Cao1, Yanni Hu2, Xingxin Li3, Yanfang Zhang3
1Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, China; 2Department of Hematology, Children’s Hospital of Chongqing Medical University, China; 3Experimental Teaching Center, Chongqing Medical University, China

SUCCESSFUL AUTOLOGOUS STEM CELL TRANSPLANT IN A CASE OF MULTIPLE MYELOMA WITH MECHANICAL HEART VALVES
Isha Shah1, Lalit Kumar1, Diksha Dev Yadav2, Anil Khetarpal3
1Department of Medical Oncology, Artemis Hospital, Gurugram(H); 2Department of Hematopathology, Artemis Hospital, Gurugram(H) and 3Department of Blood Transfusion, Artemis Hospital, Gurugram(H), India

THE ADVERSE THERAPEUTIC OUTCOMES AND EFFICACY LIMITATIONS ASSOCIATED WITH CAR T-CELL THERAPY IN THE TREATMENT OF MULTIPLE MYELOMA: A SYSTEMATIC REVIEW
Maifa Belghoul
NHS England, UK

BELANTAMAB MAFODOTIN + BORTEZOMIB + DEXAMETHASONE VERSUS 2L+ RELAPSED/REFRACTORY MULTIPLE MYELOMA REGIMENS: LENALIDOMIDE-EXPOSED, LENALIDOMIDE-REFRACTORY, HIGH-RISK CYTOGENIC, AND 2L-ONLY SUBPOPULATIONS: A NETWORK META-ANALYSIS
Paula Rodriguez Otero1, Joshua Richter2, Ajay Nooka3, Fredrik Schjesvold4, Emily Combe5, Leanne Cooper5, Ollie Schofield5, Indeg Sly5, Nick Ballew6, Jacopo Bitetti7, Natalie Boytsov6, Molly Purser6, Simon McNamara7
1Cancer Center Clinica Universidad de Navarra, Spain; 2Mount Sinai, USA; 3Winship Cancer Institute of Emory University, USA; 4Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Norway; 5FIECON, UK; 6GSK, USA;7GSK, Switzerland; 7GSK, UK

CIRCULATING CYTOKINE PROFILES CORRELATING RESPONSE AND CYTOKINE RELEASE SYNDROME IN MULTIPLE MYELOMA PATIENTS UNDERGOING TCES AND CAR-T CELL THERAPIES
Zhongfei Tao1, Jana, Mihályová1, Karolína Janochová2, Daniel Bílek1, David Žihala1, Lucie Broskevičová1, Soňa Procházková1 Ondrej Venglář1, Tereza Ševčiková1,2, Zdeněk Švagera2, Michaela Migašová2, Ludmila Muroňová1, Hana Plonková1, Tomáš Jelínek1, Roman Hájek1
1Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic, Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic, 2Department of Clinical Biochemistry, Institute of Laboratory Medicine, University Hospital, Institute of Laboratory Medicine, Faculty of Medicine, University of Ostrava, Czechia

MANAGEMENT OF VIRAL INFECTIONS IN RELAPSED REFRACTORY MULTIPLE MYELOMA (R/R MM) PATIENTS ON BISPECIFIC ANTIBODIES (BsAbs); SINGLE UK ACADEMIC CENTRE EXPERIENCE AND 2 CASE STUDIES
Matthew Steel, Salam Youssef, Ella Gault, Tracy Dmello, Lisa Yuen, Neeraj Kohli, Majid Kazmi, Matthew Streetly, Hugues De Lavallade, Sajitha Sachchithanantham, Dana Warcel
Guys and St Thomas NHS Trust, UK 

PHASE I STUDY OF BELANTAMAB MAFODOTIN (BELAMAF) IN COMBINATION WITH STANDARD OF CARE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TI-NDMM): DREAMM-9 UPDATED INTERIM ANALYSIS
Enrique M. Ocio11, Saad Z. Usmani1, Michał Mielnik2, Mamta Garg3, Irwindeep Sandhu4, Al-Ola Abdallah5, Youngil Koh6, Albert Oriol7, Hang Quach8, Katja Weisel9, Aránzazu Alonso Alonso10, Wojciech Janowski12, Chang-K. Min13, Karthik Ramasamy14, Ricarda Garcia Sanchez15, Paula Rodriguez-Otero16, Chris Brawley17, Jacqueline L. Egger17, Morrys C. Kaisermann18, Marek Hus19
1Memorial Sloan Kettering Cancer Center, USA; 2Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Poland, 3Leicester Royal Infirmary, UK, 4University of Alberta, Canada, 5University of Kansas Medical Center, US Myeloma Research Innovations Research Collaborative (USMIRC), USA, 6Department of Internal Medicine, Seoul National University Hospital, South Korea, 7Institut Català d’Oncologia and Institut Josep Carreras – Hospital Universitari Germans Trias i Pujol (HUGTP), Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain, 8St Vincent’s Hospital Melbourne, University of Melbourne, Australia, 9University Medical Center of Hamburg-Eppendorf, Germany, 10Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Hospital Quirón Madrid, Madrid, Spain, 11Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Spain, 12Calvary Mater Newcastle, Australia, 13Seoul St. Mary’s Hospital, South Korea, 14Oxford Translational Myeloma Centre, NDORMS, University of Oxford and Churchill Hospital, UK, 15Department of Hematology, Hospital Universitario Virgen de la Victoria, Spain, 16Cancer Center Clínica Universidad de Navarra, Spain, 17: GSK, UK, 18GSK, USA, 19Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Poland

INTEGRATED ASSESSMENT OF MEASURABLE RESIDUAL DISEASE (MRD) BY BONE MARROW FLOW CYTOMETRY AND (18) F-FDG PET/CT SCAN IN MULTIPLE MYELOMA POST TRANSPLANT: A PROSPECTIVE STUDY
Isha Shah1, Diksha Yadav2, Noaline Sinha3, Tajamul Malik3, Hemant Sachani3, Priya Tiwari1, Mukesh Patekar1, Lalit Kumar1
1Department of Medical Oncology, 2Department of Hematopathology, 3Department of Nuclear Medicine & Radio-Theranostics, Artemis Hospital, Gurugram(H), India

YOUNG PATIENT WITH MULTIPLE MYELOMA WITHOUT TRANSPLANT ACCESS: CLINICAL EVOLUTION WITH PERSISTENT POSITIVE MRD (MRD+)
Maribel Molina, Martha Cueva, Claudia Morales, Claudia Otoya
National Hospital Arzobispo Loayza, Lima, Peru

DIAGNOSTIC TIMING AND SLIM-CRAB PRESENTATIONS IN MULTIPLE MYELOMA: A REAL-WORLD HEALTHTREE CURE HUB REGISTRY STUDY (2006–2024)
Jorge Arturo Hurtado Martinez1, Felipe Flores Quiroz1, Nadine Abdallah2, Samuel Rubenstein3, Heinz Ludwig4, Jennifer Ahlstrom1, Mason Barnes1, Samuel, Bennion1, Alex Cameron1, Patricia Alejandra Flores Pérez1, Karla Mariana Castro Bórquez1, Martha Paola Anchondo Commesse1, Ana Echenique Alcázar1, Andrea Isabel Robles Espinoza1, Rachel Jensen1, Jael Antonio Liñán Esparza1, Jay Hydren1
1HealthTree Foundation, Canada, USA, Mexico; 2Mayo Clinic, USA; 3University of North Carolina-Chapel Hill School of Medicine, USA; 4Wilhelminen Cancer Research Institute, Austria

ENDOSCOPIC GASTROINTESTINAL CANCER SCREENING FINDINGS IN PATIENTS WITH MULTIPLE MYELOMA RECEIVING IMMUNOMODULATORY DRUGS
Muruvvet Seda Aydin, Gulten Korkmaz, Sezgin Pepeler, Funda Ceran, Simten Dagdas, Gulsum Ozet
Department of Hematology and Bone Marrow Transplantation, Ankara Bilkent City Hospital, Turkey

ENHANCER EXTRACHROMOSOMAL CIRCULAR DNA ANKRD28 DRIVES DRUG RESISTANCE VIA POU2F2-MEDIATED TRANSCRIPTIONAL REWIRING IN MULTIPLE MYELOMA
Binzhen Chen, Jian Hou
Department of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

EUROPEAN CLINICAL VIEWS ON THE CHALLENGES OF TREATING PATIENTS WITH AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN MULTIPLE MYELOMA
Tim Applicant d’Estrube1; Shantanu Ganguly2; Alicia O’Neill3; Sandhya Sapra4; Jorge Mouro5; Daniel Bretton6; Martin Parkinson6; Aleksandra Zapala Szufel6; Molly Purser7
1GSK, London, UK, 2GSK, Bangalore, India, 3GSK, Collegeville, Pennsylvania, USA, 4GSK, Collegeville, Pennsylvania, USA, 5GSK, Baar, Switzerland, 6Evidera, London, UK, 7GSK, Pennsylvania, USA

EUROPEAN CLINICAL VIEWS ON THE CHALLENGES OF TREATING PATIENTS WITH BISPECIFIC ANTIBODIES IN MULTIPLE MYELOMA
Tim Applicant d’Estrube1; Shantanu Ganguly2; Alicia O’Neill3; Sandhya Sapra4; Jorge Mouro5; Daniel Bretton6; Martin Parkinson6; Aleksandra Zapala Szufel6; Molly Purser7
1GSK, London, UK, 2GSK, Bangalore, India, 3GSK, Collegeville, Pennsylvania, USA, 4GSK, Collegeville, Pennsylvania, USA, 5GSK, Baar, Switzerland, 6Evidera, London, UK, 7GSK, Pennsylvania, USA

IMPACT OF LENALIDOMIDE MAINTENANCE DOSAGE ON SURVIVAL OUTCOMES IN MULTIPLE MYELOMA
Zeynep Kürüm, Ayfer Gedük
Kocaeli University School of Medicine, Turkey

IS THERE A PLACE FOR C-MYC IHC STAINING IN MULTIPLE MYELOMA REAL-WORLD CLINICAL SETTING? – SINGLE CENTER EXPERIENCE
Marija Stanić Damić1, Aron Grubešić2, Duška Petranović2, Nives Jonjić3, Andrej Belančić4, Zinaida Perić1
1Faculty of Medicine, University of Rijeka, Croatia, Clinical Hospital Center Rijeka; 2Clinical Hospital Center Rijeka, Croatia, Faculty of Medicine, University of Rijeka; 3Faculty of Medicine, University of Rijeka, Croatia, 4Clinical Hospital Center Rijeka, Croatia

MULTIPLE MYELOMA AMONG ELDERLY PATIENTS IN SUB-SAHARAN AFRICA: AN EXAMPLE FROM SENEGAL
Eric Bana; Moussa Seck
Université Cheikh Anta Diop de Dakar, Senegal

MULTIPLE MYELOMA DIAGNOSED IN A PATIENT WITH POLYCYTHEMIA VERA – A RARE CASE
Nina Petkova, Liliya Grahlyova
Hematology Clinic, Military Medical Academy-Sofa and Cytogenetic and Molecular Biology Laboratory, Military Medical Academy-Sofia, Bulgaria

MULTIPLE MYELOMA: EXPERIENCE WITH DRd THERAPY (DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE) IN TRANSPLANT INELIGIBLE PATIENTS IN A SECOND LEVEL CENTRE
Cristina Vaz Silva, Ana Felicidad De las Nieves Egea, Bianca Díaz Roldán, Juan Francisco Domínguez Rodríguez
Hospital Juan Ramón Jiménez, Spain

ROLE OF THE ER IN INITIAL DIAGNOSTIC PATHWAY OF MULTIPLE MYELOMA PATIENTS: A RETROSPECTIVE REVIEW OF 80 PRESENTATIONS AT A REGIONAL HOSPITAL
Sarah Bernstein, Sophia Campana, Pravallika Baka
Windsor Regional Hospital, Canada

THE IMPACT AND MANAGEMENT OF SOLID TUMORS DEVELOPING BEFORE OR WITHIN THE FIRST 6 MONTHS OF A DIAGNOSIS WITH MULTIPLE MYELOMA
Ebrar Uzunabdullah1, Yasa Gul Mutlu2, Serife Emre Yuksel3, Buse Gulec4, Istemi Serin5, Eren Arslan Davulcu6, Gulcin Miyase Sonmez7, Serkan Guven8, Sureyya Yigit Kaya9, Senem Maral9, Muzaffer Keklik3, Ayse Salihoglu10, Guldane Seval Cengiz7, Omur Gokmen Sevindik11
1Istanbul Medipol University, School of Medicine; 2Gaziantep City Hospital, Department of Hematology, 3Erciyes University, Department of Hematology, 4Istanbul Cerrahpasa University, Department of Hematology; 5Cam Sakura City Hospital, Department of Hematology, 6Bakirkoy Sadi Konuk Education and Training Hospital, Department of Hematology; 7Ankara University Hospital, Department of Hematology; 8Canakkale Education and Training Hospital, Department of Hematology; 9Istanbul Medipol University, Department of Hematology; 10Istanbul Cerrahpasa University Hospital, Department of Hematology, 11Istanbul Florence Nightingale Hospital, Department of Hematology, Turkey

THE SILENT THREAT OF SECONDARY MALIGNANCIES IN MULTIPLE MYELOMA PATIENTS: A COHORT STUDY FROM TURKEY IN THE ERA OF NEW DRUGS
Metban Mastanzade, Farah Jamal Taha, Ulviyya Hasanzade, Nur Yonca İnan, Meryem Merve Ören Çelik, Banuchichak Zeynallı, Simge Erdem, Mustafa Murat Özbalak, İpek Yönal Hindilerden, Mustafa Nuri Yenerel, Sevgi Kalayoğlu Beşışık
Istanbul University İstanbul Faculty of Medicine, Turkey

TRANSCRIPTOMIC AND PROTEOMIC ANALYSIS OF BONE MARROW OF PATIENTS WITH EXTRAMEDULLARY MULTIPLE MYELOMA REVEALS KEY PROTEINS ASSOCIATED WITH TRANSENDOTHEIAL MIGRATION
Ellen Purcell1, Katie Dunphy2, Paul Dowling2, Peter O’Gorman3, Despina Bazou1
1University College Dublin, 2Maynooth University, 3Mater Misericordiae, University Hospital Dublin, Ireland, UK

UNCOVERING DISPARITIES AND OPPORTUNITIES: IDENTIFYING CAR T THERAPY-ELIGIBLE PATIENTS IN A REAL-WORLD MULTIPLE MYELOMA POPULATION
Louise Potter1, Jacken Watters1, Marlette Gallo1, Stella Bowcock2, Jin-Sup Shin2, Matthew Streetly3, Hannah Patrick4, Arief Gunawan1, Samir Asher,4, Reuben Benjamin1,5
1Department of Haematological Medicine, King’s College Hospital NHS Foundation Trust, London; 2Department of Haematological Medicine, King’s College Hospital NHS Trust, Princess Royal Hospital, Orpington, London, Kent; 3Guy’s and St Thomas’ NHS Foundation Trust, London;4Lewisham and Greenwich NHS Trust, London; 5Department of Haematology, School of Cancer and Pharmaceutical Sciences, King’s College London, London, UK

DARATUMUMAB-BASED MAINTENANCE AFTER ASCT IN NEWLY DIAGNOSED MULTIPLE MYELOMA: REAL-WORLD OUTCOMES FROM A SINGLE-CENTER COHORT
Carmen Martínez Chamorro, Concepción Aláez Usón, Arancha Alonso Alonso, Virginia Pradillo Fernández, José Manuel Sánchez Ramírez
Hospital Universitario Quirónsalud Madrid, Spain

EXPERIENCE WITH DARATUMUMAB, BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (D-VRD) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS AT A TERTIARY HOSPITAL
Lola Piquer Monsonis, Raquel Ferrero Guillem, Maria Gali Sampalo, JM Sanchez Raga, Albert Perez Montaña, Antonio Gutierrez Garcia, Jorge Gines Rubio, Antonia Sampol Mayol
Spain      

SUCCESSFUL EARLY RESCUE WITH ISATUXIMAB PLUS CARFILZOMIB-DEXAMETHASONE IN DARATUMUMAB-REFRACTORY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH “NO WASHOUT PERIOD”
Paula Gili Herreros1, Patricia García Ramírez1, Xabier Gutiérrez López de Ocáriz2, Marta Callejas Charavía1, Julio García Suárez1, Juan José Gil-Fernández1
1Hospital Universitario Príncipe de Asturias, Spain; 2Hospital Universitario de Álava, Spain

THE SASP AS FRAILTY BIOMARKERS IN NEWLY DIAGNOSED MULTIPLE MYELOMA
Nadine Abdallah, Byron Smith, Thomas White, Amanda Heeren, Francis Buadi, Prashant Kappor, Angela Dispenzieri, Suzanne Hayman Eli Muchtar, David Dingli, Wilson Gonsalves, Joselle Cook, Saurabh Zanwar, Moritz Binder, Yi Lin, Nelson Leung, Taxiarchis Kourelis, Morie Gertz, Rahma Warsame, Vincent Rajkumar, Nathan Lebrasseur, Shaji Kumar, Megan Weivoda
Mayo Clinic, USA

A CASE REPORT OF REFRACTORY MULTIPLE MYELOMA (MM) WITH AMYLOIDOSIS
Jiantuo Liu, Hongrui Li, Li Jiang, Shanlin Zheng, Xuekui Qiu, Haiqin Zhang
Wuhan Kindstar Clinical Diagnostic Institute, China

CHARACTERIZATION OF LINVOSELTAMAB’S BCMA BINDING EPITOPE AND EFFICACY AGAINST BCMA MUTATIONS IN RELAPSED/REFRACTORY MUTLIPLE MYELOMA
Ken Lee, Yi Zhou, Matthew Franklin, Erica Ullman, Aynur Hermann, Glenn S. Kroog, Anita: Boyapati, Karen Rodriguez Lorenc, Eric Smith, John C. Lin, William Olson, Andres Sirulnik, Kara: Olson
Regeneron Pharmaceuticals, Inc., USA

CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) VS STANDARD OF CARE (SOC) IN PATIENTS WITH LENALIDOMIDE (LEN)-REFRACTORY MULTIPLE MYELOMA (MM) AFTER 1–3 LINES OF THERAPY: MINIMAL RESIDUAL DISEASE (MRD) NEGATIVITY IN THE PHASE 3 CARTITUDE-4 TRIAL
Lionel Karlin1, Rakesh Popat2, Albert Oriol3, Michele Cavo4, , Irit Avivi5, Wilfried Roeloffzen6, Seok Jin Kim7, Brea Lipe8, Noffar Bar9, Noemi Horvath10, Andrew Spencer11, Chang-Ki Min12, Diana Chen13, Quanlin Li14, Katherine Li15, Ana Slaughter16, Carolina Lonardi17, Nina Benachour18, Arnab Ghosh19, Martin Vogel20, Nikoletta Lendvai19, Tamar Lengil21, Nitin Patel22, Octavio Costa Filho22, Erika Florendo22, Yi Lin23
1Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France; 2University College London Hospitals, NHS Foundation Trust, London, UK; 3Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain; 4IRCCS Azienda Ospedaliero-Universitaria di Bologna, Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy; 5Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; 6University Medical Center Groningen, Groningen, Netherlands; 7Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; 8University of Rochester Medical Center, Rochester, NY, USA; 9Yale Cancer Center, Yale University, New Haven, CT, USA; 10Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, Australia; 11Alfred Health-Monash University, Melbourne, VIC, Australia; 12Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea; 13Janssen Research & Development, Shanghai, China; 14Janssen Research & Development, Apex, NC, USA; 15Janssen Research & Development, Spring House, PA, USA; 16Cilag GmbH International, Zug, Switzerland; 17Janssen, Buenos Aires, Argentina; 18Janssen Research & Development, Beerse, Belgium; 19Janssen Research & Development, Raritan, NJ, USA; 20Janssen Research & Development, Neuss, Germany; 21Janssen Global Services, Raritan, NJ, USA; 22Legend Biotech USA Inc., Somerset, NJ, USA; 23Mayo Clinic, Rochester, MN, USA

EFFICACY AND SAFETY OF WEEKLY SELINEXOR, IN COMBINATION WITH POMALIDOMIDE, AND DEXAMETHASONE (SPD) FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATES FROM THE PHASE 1b/2 STOMP TRIAL
Muhamed Baljevic1, Nizar Bahlis2, Rami Kotb3, Gary Schiller4, Brea Lipe5, Sumit Madan6, Heather Sutherland7, Suzanne Lentzsch8, Natalie Callander9, Noa Biran10, Dane Van Domelen11, Tomer Mark11, Darrell White12
1Vanderbilt University Medical Center, USA; 2University of Calgary, Charbonneau Cancer Research Institute, Canada; 3CancerCare Manitoba, Canada; 4David Geffen School of Medicine, University of California, USA; 5University of Rochester, USA; 6Banner MD Anderson Cancer Center, USA; 7Vancouver General Hospital, Canada; 8Columbia University, USA; 9University of Wisconsin, Carbone Cancer Center, USA; 10 Hackensack University Medical Center, USA; 11Karyopharm Therapeutics, USA; 12Queen Elizabeth II Health Sciences Centre and Dalhousie University, Canada

IMPACT OF SELINEXOR DOSE REDUCTIONS ON SELINEXOR, BORTEZOMIB, DEXAMETHASONE (SVD) OUTCOMES IN PATIENTS (PTS) WITH LENALIDOMIDE (LEN)-REFRACTORY MULTIPLE MYELOMA (MM): BOSTON TRIAL SUBGROUP ANALYSIS
Sosana Delimpasi1, Ivan Špička2, Jason Butler3, Don Stevens4, Mercedes Mesa5, Ceri Bygrave6, Giovanni Merlo7, Charles la Porte8, Meletios Dimopoulos9
1Evangelismos Hospital, Hematology/Lymphomas and BMT Unit, Greece; 2Charles University and General University Hospital, Czechia; 3Australia Royal Brisbane and Women’s Hospital, Australia; 4Norton Cancer Institute, St. Matthews Campus, USA; 5Vall d’Hebron University Hospital, Spain; 6University Hospital of Wales, Canada; 7Menarini Group, Italy; 8Menarini Group, Belgium; 9National and Kapodistrian University of Athens, School of Medicine, Alexandra Hospital, Greece

INFECTIOUS RISK OF RELAPSED/ REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH BISPECIFIC ANTIBODIES
Fernanda Braga Seganfredo1,2, Daniela Sofia Neves de Sousa Maia1, Hélder Martins Ranhada1, Marta Pires de Lima1, Maria do Céu Trindade1, Susana Maria Carvalho1, Paulo Bernardo1, Manuela Bernardo1, Maria Gomes da Silva1, Fernando Leal da Costa1
1Hematology Department, 2Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal

IS IT TIME TO FIGHT MULTI-REFRACTORINESS IN PATIENTS WITH FIRST RELAPSE IN MULTIPLE MYELOMA IN ITALY?
Sonia More’1, Laura Corvatta2, Francesca Mostardi1, Erika Morsia1, Antonella Poloni1, Massimo Offidani1
1Clinica di Ematologia, AOU delle Marche – Dipartimento di Scienze Cliniche e Molecolari, UNIVPM, Ancona; 2Medicina Interna, Ospedale E. Profili, Fabriano, Italy

LINVOSELTAMAB IN PATIENTS IDENTIFYING AS BLACK OR AFRICAN AMERICAN WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM LINKER-MM1
Jeffrey A. Zonder1, Joshua, Richter2, Sundar Jagannath2, Hans C. Leee3, Attaya Suvannasankha4, James E.  Hoffman5, Mansi R. Shah6, Suzanne Lentzsch7, Naresh Bumma8, Rachid Baz9, Swathi Namburi10, Ka Lung Wu11, Joseph J. Maly12, Rebecca, Silbermann13, Chang-Ki Min14, Matthew Pianko15, Marie-Christiane Vekemans16, Markus Munder17, Ja Min Byun18, Joaquín Martínez-López19, Michelle, DeVeaux20, Dhruti Chokshi20, Megan Seraphin20, Kate Knorr20, Glenn S. Kroog20, Madhav V. Dhodapkar21
1Karmanos Cancer Institute, USA, 2Icahn School of Medicine at Mount Sinai, USA, 3The University of Texas MD Anderson Cancer Center, USA, 4Indiana University Simon Cancer Center and Roudebush VAMC, USA, 5University of Miami Health System, USA, 6Rutgers Cancer Institute of New Jersey, USA, 7Columbia University Medical Center, USA; 8The Ohio State University Comprehensive Cancer Center, USA; 9Department of Malignant Hematology, H. Lee Moffitt Cancer Center, USA; 10Swedish Cancer Institute, USA; 11Ziekenhuis Netwerk Antwerpen Stuivenberg, Belgium; 12Norton Cancer Institute, USA: 13Knight Cancer Institute, Oregon Health & Science University, USA; 14Department of Hematology, Seoul St. Mary’s Hospital, The Catholic University of Korea, South Korea; 15University of Michigan, Rogel Cancer Center, USA, 16Department of Internal Medicine, Université Catholique de Louvain (UCLouvain), Belgium; 17Third Department of Medicine, University Medical Center of the Johannes Gutenberg University, Germany, 18Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, South Korea; 19Hospital Universitario 12 de Octubre, Universidad Complutense, CNIO, Spain; 20Regeneron Pharmaceuticals, Inc., USA; 21Emory University School of Medicine, USA

MAGNETISMM-20: EFFICACY AND SAFETY OF ELRANATAMAB PLUS CARFILZOMIB AND DEXAMETHASONE (EKD) FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Xavier Leleu1, Michael H. Tomasson2, Eli Gabayan3, Syed Abbas Ali4, Gabriel Afram5, Sona Ghorashi6, Trish Creel6, Luisa Paccagnella6, Jay Cheng6, Ola Landgren7
1Department of Hematology, Centre Hospitalier Universitaire de Poitiers, France; 2Internal Medicine, University of Iowa, USA; 3Beverley Hills Cancer Center, USA; 4Department of Oncology, The Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, USA; 5Pfizer Inc, Sweden; 6Pfizer Inc, USA; Sylvester Comprehensive Cancer Center, USA

SAFETY ANALYSIS OF DARATUMUMAB BASED REGIMENS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA IN A HOSPITAL IN COLOMBIA: REAL-LIFE RESULTS
Luisa María Betancourth Gil, Elizabeth Arrieta, Oriana Arias, Joaquín Rosales, Álvaro Mondragón
Fundación Valle del Lili, Colombia

SAFETY RESULTS FROM REALiTEC: A MULTI-COUNTRY OBSERVATIONAL RETROSPECTIVE STUDY OF TECLISTAMAB IN RELAPSED/REFREACTORY MULTIPLE MYELOMA OUTSIDE OF CLINICAL TRIALS
Aurore Perrot1, Katarina Uttervall2, Martin Kortüm3, Sarah Leeth Farmer4, Michele Cavo5, Bhuvan Kishore6, Caroline Jacquet7, Maria Casanova8, Markus Hansson9, Katja Weisel10, Hila Magen11, Carmine Liberatore12, Charlotte Toftmann Hansen13, Moshe E. Gatt14, Tamir Shragai15, Matteo Claudio Da Vià16, Teresa De Soto Alvarez17, Mathew Streetly18, Marc-Steffen Raab19, Salomon Manier20, Jesper Aegesen21, Rana Takchi22, Peter Hu23, Vadim Strulev24, Eva Rubio-Azpeitia25, Claire Albrecht26, Diptendu Santra27, Rakesh Popat28
1CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France; 2Medical Unit Hematology, Karolinska University Hospital, Stockholm, Sweden; 3Department of Medicine II, University Hospital of Würzburg, Würzburg, Germany; 4Department of Hematology, Vejle Hospital, Vejle, Denmark, 5IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy; Dipartimento di Scieze Mediche e Chirurgiche, Universitá di Bologna, Bologna, Italy; 6University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; 7Service d’hématologie, CHU de Nancy, Vandoeuvre-lès-Nancy, France; 8Hospital Costa del Sol, Marbella, Spain; 9Section of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden; 10Universitätsklinikum Hamburg-Eppendorf, Medizinische Klinik und Poliklinik, Hamburg, Germany; 11Department of Hematology Chaim Sheba Medical Center, Ramat-Gan, Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel; 12Hematology Unit, Department of Oncology and Hematology, Ospedale Santo Spirito, Pescara, Italy; 13Department of Haematology, Odense University Hospital, Odense, Denmark; 14Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; 15Department of Haematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel; Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; 16Department of Hematology, IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; 17Hematology Department, La Paz University Hospital, IdiPAZ Research Institute, Madrid, Spain; 18Department of Clinical Haematology, Guys Hospital, Guys and St. Thomas’ NHS Foundation Trust, London, UK; 19Heidelberg Myeloma Center, Department of Medicine, University Hospital Heidelberg, Heidelberg, Germany; 20Department of Hematology, University of Lille, Centre Hospitalier Universitaire Lille, Lille, France; 21Department of Medicine, Ryhov County Hospital, Jönköping, Sweden; 22Johnson & Johnson Middle East FZ-LLC; Beirut, Lebanon; Statistics & Decision Science, J&J Innovative Medicine Research & Development, USA; 24Janssen Pharmaceutica NV, Beerse, Belgium; 25Janssen Cilag, Madrid, Spain; 26Janssen Cilag, Issy les Moulineaux, France; 27Parexel International, United Kingdom, on behalf of Janssen Cilag, Issy les Moulineaux, France; 28NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK

TALQUETAMAB (TAL) + DARATUMUMAB (DARA) + POMALIDOMIDE (POM) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE PHASE 1B TRIMM‑2 STUDY
Nizar, Bahlis1, Niels WCJ, van de Donk2, Donna Reece3, Manisha Bhutani4, Bhagirathbhai Dholaria5, Anita D’Souza6, Thomas G. Martin7, John McKay8, Alfred L. Garfall9, Amrita Krishnan10, Kalpana Bakshi11, Lijuan Kang12, Lien Vandenberk13, Thomas Prior14, Jaszianne Tobert15, Ajai Chari16
1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada, 2Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands, 3Princess Margaret Cancer Centre, Toronto, ON, Canada, 4Levine Cancer Institute / Wake Forest School of Medicine, Charlotte, NC, USA, 5Vanderbilt University Medical Center, Nashville, TN, USA, 6Medical College of Wisconsin, Milwaukee, WI, USA, 7Helen Diller Family Comprehensive Cancer Center, San Francisco Medical Center, University of California, San Francisco, CA, USA, 8Wake Forest University School of Medicine, Winston-Salem, NC, USA, 9Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, 10City of Hope Comprehensive Cancer Center, Duarte, CA, USA, 11Janssen Research & Development, Spring House, PA, USA, 12Janssen Research & Development, Spring House, PA, USA, 13Janssen Research & Development, Antwerp, Belgium, 14Janssen Research & Development, Spring House, PA, USA, 15Janssen Research & Development, Spring House, PA, USA, 16University of California, San Francisco, San Francisco, CA, USA

TALQUETAMAB IN PATIENTS WITH MULTIPLE MYELOMA: A SINGLE-CENTER CASE SERIES
Ana Felicidad de las Nieves, Cristina Vaz Silva, Bianca Díaz Roldán, Carmen Gil Barroso
Hospital Juan Ramón Jiménez SAS, Spain

TRANSFUSION-RELATED SAFETY AND ACCESS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH DARATUMUMAB-BASED REGIMENS: REAL-WORLD RESULTS FROM A HOSPITAL IN COLOMBIA
Luisa María Betancourth Gil1, Elizabeth Arrieta1, Oriana Arias1, Joaquin Rosales1, Marcela Quintero2
1Fundación Valle del Lili and 2Universidad del Valle, Santiago de Cali, Valle del Cauca, Colombia

MONOCLONAL GAMMOPATHIES OF CLINICAL SIGNIFICANCE (MGCS), AN UNDER RECOGNIZED ENTITY AND THE SIGNIFICANCE OF AN MGUS TUMOR BOARD
Christy Samaras, Sandy Mazzoni, Beth Faiman, Cynthia Scott, Saveta Mathur, Kimberly Hamilton, Faiz Anwer, Shahzad Raza, Willem Van Heeckeren, Jason Valent, Jack Khouri, Lou Williams
Cleveland Clinic Foundation, USA

MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE: A CASE OF DIAGNOSTIC REEVALUATION AND TREATMENT SUCCESS
Pilar Perez Garcia, Bianca Diaz Roldan, Juan Francisco Dominguez Rodriguez, Cristina Vaz Silva, Ana Felicidad De las Nieves Egea
Hospital Juan Ramón Jimenez, Huelva, Spain

REAL-WORLD SURVEILLANCE, TREATMENT STRATEGIES, AND PATIENT PERSPECTIVES ON EARLY INTERVENTION IN SMOLDERING MULTIPLE MYELOMA: A CROSS-SECTIONAL SURVEY STUDY
Nadine Abdallah, Mason Barnes, Jorge Arturo Hurtado Martínez, Jay Hydren, Joselle Cook, Rachel Jensen, Felipe Flores, Shaji Kumar, Vincent Rajkumar, Jenny Ahlstrom
Mayo Clinic and HealthTree Foundation, USA

A WEB-BASED RISK CALCULATOR FOR MACHINE LEARNING–DERIVED RISK SCORES IN MULTIPLE MYELOMA
Carlos Pérez Míguez1, Adrián Mosquera Orgueira2,3, Marta Sonia González Pérez3, María Victoria Mateos Manteca4
1GRHECO-Xen, Instituto de Investigación Sanitaria de Santiago, Santiago de Compostela, Galicia; 2Department of Hematology and Hemotherapy, University Hospital of Santiago, Santiago de Compostela; 3Computational Hematology and Genomics Group, IDIS, Santiago de Compostela; 4University Hospital of Salamanca, IBSAL, CIC, and CIBERONC, Salamanca, Spain

ADMINISTRATION OF INJECTABLE ANTICANCER DRUGS IN HOSPITALIZATION AT HOME (HAH): THE PROSPECTIVE CARFIL-HAD PILOT STUDY CONFIRMS THE FEASIBILITY AND ECONOMIC INTEREST OF THE HOME ADMINISTRATION OF SHORT DURATION INFUSIONS OF CARFILZOMIB FOR THE TREATMENT OF MULTIPLE MYELOMA
Mohamed Toutati1, Yasmine Khayati1, Sophie Bastide2, Camille Villesuzanne3, Gaëlle Maillan1, Caroline Streitcher3, Catherine Brillat4, Sophie Sardin5, Stéphane Girault3, Murielle Roussel1
1CHU de Limoges, France; 2HEVA, France; 3CH de Brive, France; 4HAD Relai Santé Brive, France; 5HAD Santé Service Limousin, France

FREQUENCY AND CLINICAL SIGNIFICANCE OF INCIDENTAL SECONDARY NEOPLASMS IN PET-CT IMAGES OF MULTIPLE MYELOMA PATIENTS
Eren Arslan Davulcu1, Elis Atakan2, Nazlı Tuğba Şentürk2, Murat Polat3, Emine Gültürk1, Fehmi Hindilerden1
1Bakırköy Dr Sadi Konuk Research and Training Hospital, Hematology Clinic, 2Bakırköy Dr Sadi Konuk Research and Training Hospital, Internal Medicine Clinic, 3Bakırköy Dr Sadi Konuk Research and Training Hospital, Nuclear Medicine Clinic, Turkey

HEALTH-RELATED QUALITY OF LIFE CHANGES IN MULTIPLE MYELOMA PATIENTS: THE EXPLORE STUDY
Rui Bergatim1, Conceição Constanço2, Helena Martins3, Ilídia Moreira4, Catarina Geraldes5, Paulo Bernardo6, Cátia Gaspar7, Rita Jaime8, Fernando Leal da Costa9
1Centro Hospitalar Universitário São João; 2Centro Hospitalar Tondela-Viseu; 3Centro Hospitalar Lisboa Norte, 4Unidade Local de Saúde de Matosinhos, 5Centro Hospitalar e Universitário de Coimbra, 6Hospital da Luz, 7CUF Descobertas, 8J&J Portugal, 9Instituto Português de Oncologia, Lisboa, Portugal

ONLINE CLINICIAN EDUCATION RESULTS IN PERFORMANCE CHANGES IN CLINICAL PRACTICE RELATED TO PATIENT-CENTERED CARE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA
Victoria Harvey-Jones1, Sanneke Koekkoek1, Chii Fong1, Vincent Claus2, Paula Rodriguez Otero3, Mohamad Mohty4
1Medscape Education Global, London, UK, 2Myeloma Patients Europe AISBL, 3Hematology Department University of Navarra, Pamplona, Spain, 4Hematology and Cellular Therapy Department, Hospital Saint-Antoine Sorbonne University, Paris, France

PLASMABLASTIC LYMPHOMA IN IMMUNOCOMPETENT PATIENTS: CLINICAL CASES REPORT
Chaaouri Wiem, Wafa Miled, Malek Sayadi, Raoudha Mansouri, Raihane Benlakhal, Karim Kacem
Aziza Othmana Hospital, Tunisia

POTENTIAL DELAYS IN MYELOMA DIAGNOSIS ARE ILLUSTRATED BY THE RELATIONSHIP BETWEEN PRE-DIAGNOSTIC ROUTINE LABORATORY TESTS AND TESTING FOR MYELOMA: A SOUTH AFRICAN CONTEXT
Ryan Aylward1, Karryn Brown2, Brigid McMillan2, Jenna Oosthuizen2, Gamuchirai Tadzimirwa3, Vernon Louw4, Estelle Verburgh3
1Department of Internal Medicine, 2Department of Medicine, 3Division of Clinical Haematology, Groote Schuur Hospital, Department of Medicine, University of Cape Town, South Africa; 4Department of Medicine, University of Stellenbosch, South Africa

REVERSIBLE DIFFUSE CHOROIDAL LEAKAGE ASSOCIATED WITH DARATUMUMAB AND SUCCESSFULLY MANAGED WITH CONTINUED DESENSITIZATION THERAPY
Metban Mastanzade, Zafer Cebeci, Kıvanç Koruk, Kerem Yiğit, Sevgi Kalayoğlu Beşışık
Istanbul University İstanbul Faculty of Medicine, Turkey

SLIM-CRAB DIAGNOSTIC FEATURES AND THEIR ASSOCIATION WITH MSMART 3.0 RISK IN MULTIPLE MYELOMA: A REAL-WORLD HEALTHTREE CURE HUB REGISTRY STUDY
Jorge Arturo Hurtado Martinez1, Felipe Flores Quiroz1, Nadine Aballah2, Samuel Rubinstein3, Heinz Ludwig4, Jennifer Ahlstrom1, Mason Barnes1, Samuel Bennion1, Alex Cameron1, Patricia Alejandra Flores Pérez1, Karla Mariana Castro Bórquez1, Martha Paola Anchondo Commesse1, Ana Echenique Alcázar1, Andrea Isabel Robles Espinoza1, Rachel Jensen1, Jael Antonio Liñán Esparza1, Jay Hydren1
1HealthTree Foundation, Canada, USA, Mexico; 2Mayo Clinic, USA; 3University of North Carolina-Chapel Hill School of Medicine, USA; 4Wilhelminen Cancer Research Institute, Austria